OTLC
Oncotelic Therapeutics, Inc.
1W: -0.8%
1M: -5.8%
3M: -50.1%
YTD: -49.0%
1Y: -42.3%
3Y: -27.8%
5Y: -84.1%
$0.04
+0.00 (+0.00%)
Weekly Expected Move ±16.5%
$0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$17.7M
52W Range0.02-0.11
Volume230,700
Avg Volume296,696
Beta-0.68
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOVuong Trieu
Employees26
SectorHealthcare
IndustryBiotechnology
IPO Date1993-08-26
Websiteoncotelic.com
29397 Agoura Road
Agoura Hills, CA 91301
US
Agoura Hills, CA 91301
US
650 635 7000
About Oncotelic Therapeutics, Inc.
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.
Latest News
Oncotelic Therapeutics Announces Strategic Partnership with TechForce Robotics to Commercialize PDAOAI-Enhanced GMP Robotics Platform
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Announces Expanded IP Coverage, Strengthening Position in Biotech Evolution
Oncotelic Therapeutics, Inc. Showcases Multi-Year Execution and Validation, Enters 2026 with Late-Stage Momentum Across Diversified Pipeline
Oncotelic Therapeutics Details PDAOAI Platform and Opens Access to Its Total TGF-β Knowledge Corpus
Oncotelic Therapeutics and Brush and Key Foundation Announce Publication in International Journal of Molecular Sciences Highlighting Context-Dependent Biomarkers in Liver and Pancreatic Cancer
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Trieu Vuong | A-Award | 4,426 | — | 2026-01-22 |
| Trieu Vuong | A-Award | 4,065 | — | 2025-11-17 |
| Trieu Vuong | P-Purchase | 104,000 | $0.01 | 2025-07-10 |
| Trieu Vuong | P-Purchase | 1 | $0.01 | 2025-07-09 |
| Trieu Vuong | P-Purchase | 94,736 | $0.01 | 2025-07-08 |